NASDAQ:VSTM
Verastem Stock News
$11.50
-0.630 (-5.19%)
At Close: May 17, 2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Jan 2024
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purch
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential be
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
09:08am, Wednesday, 13'th Dec 2023
As horror film fans know, there's safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. Don't get me wrong – if you find yourself facing t
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has in
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
04:17pm, Sunday, 03'rd Dec 2023
If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clar
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
02:22pm, Wednesday, 22'nd Nov 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
01:32pm, Wednesday, 22'nd Nov 2023
Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Verastem: Potential Accelerated Approval Filing In H1 2024
01:40am, Sunday, 12'th Nov 2023
An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to kee
Verastem: Signs Of Life For A Beaten-Down Equity
09:00pm, Wednesday, 04'th Oct 2023
Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pat
Verastem Oncology to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 05'th Sep 2023
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate
Verastem: Updated Avutometinib Data Brings My Position Out Of Mothballs
04:20am, Sunday, 11'th Jun 2023
Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment of LGSOC. The market was impressed with the data
Trading Penny Stocks This Week? 3 Mistakes to Avoid
06:00am, Tuesday, 30'th May 2023
Trading penny stocks can be an exhilarating venture, offering the potential for significant returns. These low-cost shares, often priced under $5, represent a unique opportunity to participate in the
Trading Penny Stocks in the Tech Sector: Must Knows
06:55am, Saturday, 27'th May 2023
The tech sector, a perpetually booming industry, presents an ocean of opportunities for investors, particularly those interested in trading penny stocks. These are low-priced stocks, typically trading
4 Penny Stocks To Watch Under $5 With Big News This Week
01:41pm, Friday, 26'th May 2023
Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity.
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
07:05am, Tuesday, 18'th Apr 2023
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at